

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions and listings of claims in the application:

1. (Withdrawn) A method for enhancing survival or proliferation, or both, of a neural stem cell in a liquid medium, the method comprising the step of overexpressing Galectin-1 in the neural stem cell.
2. (Withdrawn) A method for enhancing survival or proliferation, or both, of a neural stem cell in a liquid medium, the method comprising the step of overexpressing Galectin-3 in the neural stem cell.
3. (Withdrawn) A method for enhancing survival or proliferation, or both, of a neural stem cell in a liquid medium, the method comprising the step of culturing the neural stem cell in a liquid medium containing Galectin-1.
4. (Withdrawn) A method for enhancing survival or proliferation, or both, of a neural stem cell in a liquid medium, the method comprising the step of culturing the neural stem cell in a liquid medium containing Galectin-3.
5. (Withdrawn) The method of claim 1 or 3, wherein the liquid medium comprises a neural stem cell conditioned medium.
6. (Withdrawn) The method of claim 1 or 3, wherein the liquid medium comprises a neurosphere conditioned medium.
7. (Withdrawn) The method of claim 1 or 3, wherein the liquid medium comprises an OP cell line conditioned medium.

8. (Withdrawn) A pharmaceutical composition comprising as an active ingredient a neural stem cell in which Galectin-1 is overexpressed and improving a higher cerebral function damaged by cerebral ischemia .

9. (Withdrawn) A pharmaceutical composition comprising as an active ingredient a neural stem cell in which Galectin-3 is overexpressed, and improving a higher cerebral function damaged by cerebral ischemia .

10. (Withdrawn) The pharmaceutical composition of claim 8 or 9, wherein the higher cerebral function is motor function.

11. (Withdrawn) The pharmaceutical composition of claim 8, wherein the higher cerebral function is sensory function.

12. (Withdrawn) A therapeutic method for cerebral ischemia, comprising improving a symptom derived from cerebral ischemia by transplanting a neural stem cell in which Galectin-1 is overexpressed in a mammalian other than a human.

13. (Withdrawn) A therapeutic method for cerebral ischemia, comprising improving a symptom that originates in cerebral ischemia by transplanting a neural stem cell in which Galectin-3 is overexpressed in a mammalian other than a human.

14. (Withdrawn) An enhancer for enhancing neurite extension when a neural stem cell differentiates, the enhancer comprising Galectin-1 or Galectin-3 as an active ingredient.

15. (Withdrawn) A method for enhancing neurite extension when a neural stem cell differentiates, the method comprising the step of overexpressing Galectin-1 in the neural stem cell.

16. (Withdrawn) A method for enhancing neurite extension when a neural stem cell differentiates, the method comprising the step of overexpressing Galectin-3 in the neural stem cell.

17. (Withdrawn) An enhancer for enhancing *in vivo* proliferation of a neural stem cell in a vertebrate, the enhancer comprising Galectin-1 or Galectin-3 as an active ingredient.

18. (Currently Amended) A method for enhancing *in vivo* proliferation of ~~[[a]]~~ neural stem ~~[[cell]]~~ cells in a vertebrate, comprising administering an effective amount of Galectin-1 to the vicinity of the neural stem cells in the brain of the vertebrate, wherein administration of the effective amount of Galectin-1 enhances proliferation of neural stem cells.

19. (Previously Presented) The method of claim 18, wherein the vertebrate is normal.

20. (Withdrawn) An enhancer for enhancing *in vivo* proliferation of an SVZ astrocyte in a vertebrate, the enhancer comprising Galectin-1 or Galectin-3 as an active ingredient.

21. (Currently Amended) A method for enhancing *in vivo* proliferation of ~~[[a]]~~ subventricular zone (SVZ) ~~astrocyte~~ astrocytes in a vertebrate, comprising administering an effective amount of Galectin-1 to the vicinity of the neural stem cells in the brain of the vertebrate, wherein administration of the effective amount of Galectin-1 enhances proliferation of SVZ astrocytes.

22. (Previously Presented) The method of claim 21, wherein the vertebrate is normal.

23. (Withdrawn) A method for assaying a target substance added into a liquid medium for activity that enhances survival or proliferation, or both, of a neural stem cell, the method comprising the steps of:

seeding a neural stem cell at a clonal concentration, using an assay medium composed of a basal medium incapable of inducing proliferation of a neural stem cell under the situation of having been seeded at the clonal concentration;

and

determining whether or not the seeded neural stem cell can proliferate in the assay medium.

24. (Withdrawn) A method for assaying a target substance added into a liquid medium for activity that enhances survival or proliferation, or both, of a neural stem cell, the method comprising the steps of:

selecting a CD15+ neural stem cell;

seeding the CD15+ neural stem cell selected at a clonal concentration, using an assay medium composed of a basal medium incapable of inducing proliferation of a neural stem cell under the situation of having been seeded at the clonal concentration;

and

determining whether or not the seeded neural stem cell can proliferate in the assay medium.

25. (Withdrawn) The assay method of claim 23 or 24, wherein the seeding is performed at the clonal concentration by placing one neural stem cell per well of a culture plate.

26. (Withdrawn) A screening method for identifying an active substance with activity that enhances survival or proliferation, or both, of a neural stem cell among a plurality of target substances, the method comprising identifying the active substance by the assay method of any one of claims 23 to 25.

27. (Previously Presented) The method of claim 21, wherein the Galectin-1 is a C-S mutant Galectin-1 in which at least one cysteine residue among the cysteine residues possessed by Galectin-1 is mutated to a serine residue.

28. (Withdrawn) The pharmaceutical composition of claim 8 or 11, wherein the Galectin-1 is a C-S mutant Galectin.

29. (Withdrawn) The therapeutic agent for cerebral ischemia of claim 12, wherein the Galectin-1 is a C-S mutant Galectin.

30. (Withdrawn) The enhancer of any one of claim 14, 17, or 20, wherein the Galectin-1 is a C-S mutant Galectin.

31. (Previously Presented) The method of claim 18, wherein the vertebrate has a neurological disorder.

32. (Currently Amended) A method for treating a patient with a neurological disorder, comprising enhancing *in vivo* proliferation of ~~[[a]]~~ neural stem ~~[[cell]]~~ cells in the patient by administering an effective amount of Galectin-1 ~~to the vicinity of the~~ ~~neural stem cells in the brain of the patient, wherein administration of the effective~~ amount of Galectin-1 enhances proliferation of neural stem cells.

33. (Previously Presented) The method of claim 32, wherein the neurological disorder is cerebral ischemia or a neural degenerative disease.

34. (Previously Presented) The method of claim 18, wherein the Galectin-1 is a C-S mutant Galectin-1 in which at least one cysteine residue among the cysteine residues possessed by Galectin-1 is mutated to a serine residue.

35. (Previously Presented) The method of claim 21, wherein the vertebrate has a neurological disorder.

36. (Currently Amended) A method for treating a patient with a neurological disorder, comprising enhancing *in vivo* proliferation of ~~[[an]]~~ SVZ ~~astrocyte~~ astrocytes in the patient by administering an effective amount of Galectin-1 ~~to the vicinity of the neural stem cells in the brain of the patient, wherein administration of the effective~~ amount of Galectin-1 enhances proliferation of SVZ astrocytes.

37. (Previously Presented) The method of claim 36, wherein the neurological disorder is cerebral ischemia or a neural degenerative disease.

38. (Previously Presented) The method of claim 18, wherein Galectin-1 is administered to the lateral ventricle of the brain.

39. (Previously Presented) The method of claim 21, wherein Galectin-1 is administered to the lateral ventricle of the brain.

40. (Previously Presented) The method of claim 32, wherein Galectin-1 is administered to the lateral ventricle of the brain.

41. (Previously Presented) The method of claim 36, wherein Galectin-1 is administered to the lateral ventricle of the brain.